Home | Welcome to Contract Pharma   
Last Updated Saturday, October 25 2014
Print RSS Feed

Amgen Recalls Lots of Aranesp



Published August 14, 2014
Amgen initiated a voluntary recall on June 26th for nine packaged lots of Aranesp (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and hospital pharmacies due to the potential presence of cellulose and/or polyester particles observed in a small number of syringes during a routine quality check. The lots are being recalled as a precautionary measure, and to date, there have been no adverse events reported attributed to the presence of these particles.
 
The FDA has determined that health implications related to the particles would vary, depending on route of administration, amount of particulate matter injected, size of the particles, and the patient's underlying medical condition, which may elicit inflammatory and allergic responses, and may be life-threatening.
 
In the U.S., Aranesp is indicated for the treatment of anemia associated with chronic renal failure, or in patients with non-myeloid malignancies with chemotherapy induced anemia. Aranesp distributed in the U.S. is not impacted by this recall.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On